< Zurück zu den aktuellen Neuigkeiten & Events

Neuigkeiten

Notice from the European Patent Office dated 22 February 2021 concerning the amendment of Rules 19 and 143 EPC

März 2021

From 1 April 2021, inventors will no longer be notified by the EPO about being named in a patent application. In addition, applicants will no longer be required to indicate the full address of the inventor in the application, only the country and place of residence.

Amended Rule 19 (comes into force 1 April 2021):
  • Inventors are no longer notified by the EPO about their designation.
  • Applicants are no longer required to indicate the full address of the inventor only the country, city and post code.
  • Online filing tools will be updated so that they no longer have a dedicated field for entering a full address; nor will there be a dedicated field for “Company” or “Department” for inventors.
Amended Rule 143 (comes into force 1 Nov 2021):
  • Full addresses of inventors are no longer published in the EP patent register – only the country and place of residence.

Rule 20(1) still holds and is unaffected by either amended Rule 19 or Rule 143. An inventor can therefore still waive their right to be mentioned.

Reasons for the Changes:

Read the article here.

The EPO sends letters to notify inventors that they have been named on an application which is a considerable administrative burden (530,194 letters were sent in 2019 costing 307,000 EUR). In addition many of these letters are undeliverable due to incorrect addresses (36,000 in total). Updating online filing tools on the EPO IT systems will cost 50,000 EUR initially but save money in the long run.

Furthermore, due to data protection the EPO feel it is unnecessary to have the whole of the inventor’s address published on the EP patent register and that the name and city of the inventor is sufficient.

If you would like further advice on this or any other matter, please contact your usual HGF attorney or visit our Contact Page to get in touch with your nearest HGF office.

Aktuelle Neuigkeiten

HGF Director Promotions

We are pleased to announce a number of director promotions that will take effect from 1st December 2025. These individuals have demonstrated exceptional expertise, commitment, and leadership within their respective …

Weiterlesen

UK IPO fees to increase from 1 April 2026

Whilst the fee changes are subject to parliamentary approval, they are almost certain to take effect – read on to learn more. The United Kingdom Intellectual Property Office (UK IPO) …

Weiterlesen

Mycelium Meets Market Reality: The Quiet Role of IP in Scaling Sustainable Materials

Fungal materials are increasingly used in applications ranging from sustainable packaging and leather alternatives to construction composites, textiles, and biotechnology. These developments are transforming fungi from a niche research subject …

Weiterlesen
Event - 24. bis 25. November 2025

HGF Partners with 3AF for the P2I2025 Symposium

HGF are pleased to be a partner of P2I2025, the annual symposium organised by the Intellectual Property Commission of the French Aeronautics and Astronautics Association (3AF). The event brings together …

Veranstaltungsdetails

Retailers liability and AI Applications

The question of whether the user (consumer) or the provider of an AI application is liable for the infringement of intellectual property rights as a result of the use of …

Weiterlesen
Event - 11. November 2025

OIS Investor Forum - Jeffries

HGF is proud to be sponsoring the OIS Investor Forum on 18th November. One of the premier gatherings for leaders, innovators, and investors across the healthcare industry. The forum covers …

Veranstaltungsdetails

From Stripes to Supermarkets: The Court of Appeal Reaffirms the Need for Precision in Trade Mark Law

On 23 October 2025, Lord Justice Arnold delivered two landmark Court of Appeal decisions addressing trade mark registrability: Thom Browne Inc & Anor v adidas AG [2025] EWCA Civ 1340 …

Weiterlesen

Protecting Digital Health innovation in the AI revolution

As artificial intelligence (AI) continues to transform healthcare, from diagnostic imaging and drug discovery to wearable devices and clinical decision support, questions around how to protect these advancements have become …

Weiterlesen